China Resources Jiangzhong Pharmaceutical (600750) Fundamentals 2026 — P/E 17.4x, Revenue Analysis | SniperIQ
China Resources Jiangzhong Pharmaceutical (600750) is a CN-listed Healthcare company in Drug Manufacturers - Specialty & Generic with a market capitalization of ¥16.0B, trading at ¥25.20 on the SHH. This SniperIQ fundamentals page covers China Resources Jiangzhong Pharmaceutical's valuation (P/E 17.4x, P/B 3.7x), profitability (net margin 22.3%), revenue (¥4.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is China Resources Jiangzhong Pharmaceutical's market cap?
China Resources Jiangzhong Pharmaceutical (600750) has a market capitalization of approximately ¥16.0B, trading at ¥25.20 on the SHH. Market cap moves with the live share price.
What is China Resources Jiangzhong Pharmaceutical's P/E ratio?
China Resources Jiangzhong Pharmaceutical's trailing twelve-month P/E ratio is 17.4x, with a price-to-book (P/B) of 3.7x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is China Resources Jiangzhong Pharmaceutical?
China Resources Jiangzhong Pharmaceutical runs a net profit margin of 22.3%, a gross margin of 64.9%, and an operating margin of 27.4%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does China Resources Jiangzhong Pharmaceutical generate?
China Resources Jiangzhong Pharmaceutical reported revenue of ¥4.2B for fiscal year 2025, with net income of ¥906M and earnings per share (EPS) of 1.43. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does China Resources Jiangzhong Pharmaceutical pay a dividend?
China Resources Jiangzhong Pharmaceutical offers a trailing dividend yield of about 5.5%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is China Resources Jiangzhong Pharmaceutical financially healthy?
China Resources Jiangzhong Pharmaceutical carries a debt-to-equity ratio of 0.05x and a current ratio of 1.86x, with a market beta of 0.04. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is China Resources Jiangzhong Pharmaceutical a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For China Resources Jiangzhong Pharmaceutical (600750) the key facts are: market cap ¥16.0B, P/E 17.4x, revenue ¥4.2B, 52-week range 21.05-27.83. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track China Resources Jiangzhong Pharmaceutical's full fundamentals live
Get China Resources Jiangzhong Pharmaceutical's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.